News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer.
To coincide with the publication of the DDW eBook ‘Antibody discovery: Breakthroughs accelerating therapeutic antibodies’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP for two bispecific antibodies that treat multiple myeloma and lymphoma.
The top stories:
Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab).
The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly).
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working.
The latest eBook by DDW is out now. This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector.